Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Launch of 20 new medicines expected by 2030
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
ASG Group of Eye Hospitals has 165+ branches in 85+ cities across India and abroad
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Subscribe To Our Newsletter & Stay Updated